| Bioactivity | TAS0612 is an orally novel inhibitor of RSK、AKT and S6K. TAS0612 has broad-spectrum activity against tumor models via inhibiting cell growth[1]. |
| Name | TAS0612 |
| CAS | 2148902-58-1 |
| Formula | C27H34F3N9O2 |
| Molar Mass | 573.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Koji Ichikawa, et al. TAS0612, a novel RSK, AKT, and S6K inhibitor, exhibits antitumor effects in preclinical tumor models. Mol Cancer Ther. 2023. |
TAS0612
CAS: 2148902-58-1 F: C27H34F3N9O2 W: 573.61
TAS0612 is an orally novel inhibitor of RSK、AKT and S6K. TAS0612 has broad-spectrum activity against tumor models via i
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.